

#### Biodegradability of pharmaceuticals in biological systems treating source separated wastewater streams

K. Kujawa-Roeleveld\*, E. Schuman, T. Grotenhuis\*, D. Kràgić\*\* A. Mels\*\* and G. Zeeman\*

\*WUR Environmental Technology/\*\*LeAF







Sustainable Water management Improving Tomorrow's Cities' Health

Theme 4: Treatment of Source separated black water and/or urine

<u>Activity 2:</u> Development of treatment system for removal of pharmaceuticals from urine and black water



# Pharmaceuticals as environmental issue since late '90s

- Detection of low levels of drugs triggered a number of scientific publications, conferences, media stories and research (lots)
- Widely divergent speculations of the potential effects to wildlife - uncertainty on potential chronic effects
- Presence of xenobiotics and especially pharmaceuticals in environment, even at trace concentrations, regardless harmful or not, is not acceptable for a public



#### How pharmaceuticals reach environment?



#### Pharmaceuticals are present in drinking water







### Why current WWTP do not remove PhACs?

- Nature of the compounds
  - Persistent, very slowly biodegradable
  - Hydrophilic
  - Toxic?
  - Not volatile
  - Small concentrations (COD negligible)
- Characteristics of the plant
  - Processes involved
  - Process conditions are not optimal
  - Large streams to deal with (economy)



#### Measures

#### **1.** Upgrading existing treatment systems

- **2.** Source separation
- 3. Source control (not up to us but physicians, hospitals, pharmaceutical industry...)



#### **Source separation**





#### Excretion



## Concentrations pharmaceuticals in urine, black water and sewage (mg/L)

PhAC	Urine	Black water	Influent STP	Effluent STP (max found)
Ibuprofen	80	16	0.016	0.027
Metoprolol	5	1		0.009
Carbamazepine)	13	2.7	0.0022	0.022

Worse case scenario, all people from the target group use the same medication Undiluted urine, 1.5 L/day/person Black water collected with vacuum, 7,5 L black water/person/day Ibuprofen, DDD = 1.2 g/p/d, excretion 10% unchanged, Metoprolol DDD = 0.15 g/p/d excretion 5% unchanged, Carbamazepine DDD = 1 g/p/d, excretion 5% unchanged



# Difference between conventional- and source separation based sanitation

Higher PhACs concentrations (different biomass?)
Different configurations of treatment





### **Experimental approach**

- Selection representative compounds
- Batch tests
- Different redox conditions (AER, ANOX, AN)
- Different temperatures (10, 20, 30°C)
- Different biomass (AS, anaerobic sludge from black water digester)



## **Representative compounds**

Pharmaceutical	Therapeutic group	Log Kow	Hydrophilic / hydrophobic	pKa value at T = 20 <sup>0</sup> C <sup>2</sup>	k <sub>biol</sub> for CAS (L/ gSS/d)
Aspirin	anti- inflammatory	1.426	hydrophilic	3.5	n.a.
Ibuprofen	anti- inflammatory	3.481	Moderately hydrophobic	4.5-5.2	21–35
Diclofenac	anti- inflammatory	0.7-4.5 (pH)	varying	4.15	<0.1
Metoprolol	β – blocker	1.9	hydrophilic	9.7	n.a.
Carbamazepine	anti-epileptic	2.69	Moderately hydrophobic	<1, 13.9	n.a.
Clofibric acid	lipid regulating	2.57	Moderately hydrophobic	3.0	0.3–0.8
Bezafibrate	lipid regulating	4.25	hydrophobic	3.6	2.1–3.0
Fenofibrate	lipid regulating	5.19	hydrophobic	n.a.	n.a.



#### **Representative compounds**



![](_page_13_Picture_2.jpeg)

### **Batches**

Volume 1 L (AER, ANOX), 0.4-0.6 L (AN)

Brought to required redox

- Spiked with a 'coctail of 8 compounds' low mg/L range
- Samples taken in time intervals (t<sub>max</sub> =70 days)
- Controls (water +PhACs)

![](_page_14_Picture_6.jpeg)

![](_page_14_Picture_7.jpeg)

## Sampling and analysis

- Mixed sample
- Liquid/sludge separated
- Conservation: chloroform and storage at –75°C
- Sent to a specialised laboratory (LC(MS)<sup>2</sup>) for analysis (National Institute for Public Health and the Environment (RIVM), Laboratory for Food and Residue Analysis)

![](_page_15_Figure_5.jpeg)

acetylsalicylic acid

acetylsalicylic acid

20080305 55

F2:MRM of 1 channel,ES-

carbamazepine

F3:MRM of 2 channels,ES

20080305\_55

metoprolo

F1:MRM of 2 channels,ES+

![](_page_15_Picture_6.jpeg)

#### **Results** Background concentrations in used media

![](_page_16_Figure_1.jpeg)

![](_page_16_Picture_2.jpeg)

# Biodegradability (aspirin, ibuprofen, fenofibrate)

![](_page_17_Figure_1.jpeg)

# Biodegradability (metoprolol, bezafibrate, diclofenac)

![](_page_18_Figure_1.jpeg)

# Biodegradability (carbamazepine, clofibric acid)

![](_page_19_Figure_1.jpeg)

![](_page_19_Picture_2.jpeg)

### **Biodegradation kinetic**

PhAC	Test	k <sub>biol</sub> (L/gTS/d) range		
	AER-20	37.3 -43.9		
ASA	AER-10	15.9 -17.5		
	AN-30	0.111- 0.127 <sup>*</sup>		
FNF	AER-20	3.74 - 4.46*		
	AN-30	0.031- 0.035 <sup>*</sup>		
	AER-20	0.874 - 1.07		
IBU	AER-10	0.952 - 1.06		
IBU	ANOX-10	0.103 - 0.119		
	AN-30	0.024 - 0.026		
МТР	AER-20	0.569 - 0.691		
	AER-10	0.192 - 0.205		
B7F	AER-20	0.038 - 0.043		
	ANOX-20	0.111 - 0.120		

WAGENINGEN UNIVERSITY

![](_page_20_Picture_3.jpeg)

### **Summary of results**

	Aerobic 20ºC	Aerobic 10ºC	Anoxic 20°C	Anoxic 10ºC	Anaerobic 30ºC
ASA	+++	+++	++	++	+
FNF	+++	++	++	++	+
IBU	++	++	+	+	+
MTP	++	+	+	-	-
BZF	+/-	+/-	+	-	-
DCF	+/-	+/-	-	-	-
CBZ	-	-	-	-	-
CFA	-		-	-	-

![](_page_21_Picture_2.jpeg)

## **Classification of PhAC's**

■ <u>Group 1:</u> will be removed in a biological system

- Group 2: will be partially removed in biological systems; process optimisation (redox, SRT, HRT, X, T...) may enhance the removal
- Group 3: will be not removed in any biological system; advanced physical-chemical step(s) will be necessary

![](_page_22_Picture_4.jpeg)

## Conclusions

- Classification is needed covering the whole class of PhACs based on extended knowledge already gained (tests already performed, phys.-chem. characteristic (pKa, log K<sub>ow</sub>, chem. structure)
- Identification of the third group (how big, how relevant environmentally)
- Invest in research into advanced physical-chemical methods (chemical oxidation (O<sub>3</sub> and AOPs), photolysis, tight membrane filtration, activated carbon); optimization of processes`, especially in respect to concentrated (pre)treated flows

![](_page_23_Picture_4.jpeg)

### Acknoledgments

- This study was financed and supported by EU-funded SWITCH project (http://www.switchurbanwater.eu) and the STOWA (Dutch Foundation for Applied Water Research, http://www.stowa.nl) respectively.
- The National Institute for Public Health and the Environment (RIVM), Laboratory for Food and Residue Analysis is greatly acknowledged for development and performance of the analytical part of PhACs.

![](_page_24_Picture_3.jpeg)

![](_page_25_Picture_0.jpeg)

## Thank you!

![](_page_25_Picture_2.jpeg)

![](_page_26_Picture_0.jpeg)